Topic: mergers and acquisitions
Ajinomoto Bio-Pharma Services has concluded a deal that will allow the CDMO to operate in the gene therapy space.
In the second major buyout of a gene therapy manufacturer in the last three weeks, Catalent snapped up Paragon Bioservices in a $1.2 billion deal.
With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.
Novartis CEO Vas Narasimhan plans to spend $10 billion a year on acquisitions as he pursues high-growth markets such as gene therapy.
Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.
Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
BMS responded to Starboard Value's attempt to scuttle its $74 billion acquisition of Celgene with 46 pages laying out its reasoning for the deal.
Celgene said CEO Mark Alles hit financial and regulatory milestones to win a hefty 2018 bonus, but investors were focused on the company's troubles.
Wellington and other large funds may oppose the BMS-Celgene merger, but the math doesn't add up for a successful thumbs-down vote, analysts report.
Despite clear signs of health, the biopharma industry is under pressure to increase volume sales with M&A, Vantage analysts say.